Endothelial dysfunction in COVID-19 patients assessed with Endo-PAT2000

Published: February 17, 2022
Abstract Views: 1771
PDF: 417
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


It has been widely reported that the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) attaches human cells by using the Angiotensin Converting Enzyme 2 (ACE2) receptor, but vascular impairment described during coronavirus disease 2019 (COVID-19) infection is primarily due to the direct involvement of the endothelial cells by the virus or secondarily to the inflammatory host response is currently unknown. We therefore aimed to demonstrate in vivo the presence of endothelial dysfunction in six COVID-19 patients without cardiovascular risk factors or pre-existing cardiac condition, using the Endo-PAT 2000, a device able to measure endothelial vasodilation function in a rapid and non-invasive way. Four patients were positive for endothelial dysfunction, with RHI values between 1.13-1.56 (average value 1.32, normal values >1.67); in one of the two negative patients the reported RHI value was slightly above the cutoff (1.72). Our findings confirm that COVID-19 patients are at higher risk of developing endothelial dysfunction. In addition, our results demonstrate that endothelial impairment may occur even in the absence of cardiovascular risk factors.



PlumX Metrics


Download data is not yet available.


Tomasoni D, Italia L, Adamo M, et al. COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail 2020;22:957-66. DOI: https://doi.org/10.1002/ejhf.1871
Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;111:2605‐10. DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.510461
Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020;181:905‐13. DOI: https://doi.org/10.1016/j.cell.2020.04.004
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417‐8. DOI: https://doi.org/10.1016/S0140-6736(20)30937-5
Axtell AL, Gomari FA, Cooke JP. Assessing endothelial vasodilator function with the Endo-PAT 2000. J Vis Exp 2010;44:e2167. DOI: https://doi.org/10.3791/2167
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120-8. DOI: https://doi.org/10.1056/NEJMoa2015432

How to Cite

Cimino, Giuliana, Enrico Vizzardi, Emiliano Calvi, Edoardo Pancaldi, Greta Pascariello, Nicola Bernardi, Angelica Cersosimo, Ludovica Amore, Riccardo M. Inciardi, Riccardo Raddino, and Marco Metra. 2022. “Endothelial Dysfunction in COVID-19 Patients Assessed With Endo-PAT2000”. Monaldi Archives for Chest Disease 92 (4). https://doi.org/10.4081/monaldi.2022.2213.